000291915 001__ 291915
000291915 005__ 20250814105314.0
000291915 0247_ $$2doi$$a10.1016/j.ejca.2024.114233
000291915 0247_ $$2pmid$$apmid:39053290
000291915 0247_ $$2ISSN$$a0014-2964
000291915 0247_ $$2ISSN$$a0959-8049
000291915 0247_ $$2ISSN$$a1879-0852
000291915 0247_ $$2ISSN$$a(1990)
000291915 0247_ $$2ISSN$$a1879-2995
000291915 0247_ $$2ISSN$$a(1965)
000291915 0247_ $$2altmetric$$aaltmetric:165607886
000291915 037__ $$aDKFZ-2024-01527
000291915 041__ $$aEnglish
000291915 082__ $$a610
000291915 1001_ $$aBaum, Philip$$b0
000291915 245__ $$aAn International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations.
000291915 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
000291915 3367_ $$2DRIVER$$aarticle
000291915 3367_ $$2DataCite$$aOutput Types/Journal article
000291915 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1722250207_32764
000291915 3367_ $$2BibTeX$$aARTICLE
000291915 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291915 3367_ $$00$$2EndNote$$aJournal Article
000291915 520__ $$aHarmonized European NSCLC incidence, treatment approach, and survival based on national tumor registries are unclear.Surgery has the potential to cure NSCLC and significantly prolong survival. This large-scale international study aimed to investigate treatment variations in Europe and the USA, as well as the determinants for its utilization.The retrospective cohort study analyzed data from six European national population-based cancer registries (Belgium, Denmark, Estonia, Germany, the Netherlands, and Slovenia) and the US SEER database from 2010-2015.The study computed cancer incidence, survival, and age-standardized proportions of the use of various therapies. Multivariable logistic regression models were used to assess associations between resection and demographic and clinical parameters. A total of 428,107 records were analyzed. Among all countries, Estonia had the highest surgical resection rate (79.3 %) and the lowest radiation rate (7.3 %) for stage I patients. The Netherlands had the highest rate of radiotherapy across all years of investigation and the lowest surgery rate between 2012 and 2015. The primary treatment for early-stage NSCLC showed significant international variation, with the USA having a decrease in surgical rates from 67.6 % to 59.5 %. Resection was less frequently performed as tumor stage increased, patients aged, other lung cancer besides adenocarcinoma was present, and when the tumor site overlapped multiple lobes.Resection rates have declined in some studied European countries and the USA and resection rates vary substantially among countries. Interpretation of current scientific lung cancer evidence and international guidelines results in wide variations in patient treatment.
000291915 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000291915 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291915 650_7 $$2Other$$aIncidence
000291915 650_7 $$2Other$$aLung cancer
000291915 650_7 $$2Other$$aRadiotherapy
000291915 650_7 $$2Other$$aSBRT
000291915 650_7 $$2Other$$aSurgery
000291915 650_7 $$2Other$$aSurvival
000291915 7001_ $$0P:(DE-HGF)0$$aCardoso, Rafael$$b1
000291915 7001_ $$aLenzi, Jacopo$$b2
000291915 7001_ $$aDamhuis, Ronald A M$$b3
000291915 7001_ $$aVerhagen, Ad F T M$$b4
000291915 7001_ $$aDe Gendt, Cindy$$b5
000291915 7001_ $$aPeacock, Hanna$$b6
000291915 7001_ $$aDe Leyn, Paul$$b7
000291915 7001_ $$aChristensen, Niels L$$b8
000291915 7001_ $$aInnos, Kaire$$b9
000291915 7001_ $$aOselin, Kersti$$b10
000291915 7001_ $$aZadnik, Vesna$$b11
000291915 7001_ $$aZagarv, Tina$$b12
000291915 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b13$$udkfz
000291915 7001_ $$aWinter, Hauke$$b14
000291915 773__ $$0PERI:(DE-600)1468190-0$$a10.1016/j.ejca.2024.114233$$gVol. 209, p. 114233 -$$p114233$$tEuropean journal of cancer$$v209$$x0014-2964$$y2024
000291915 8564_ $$uhttps://inrepo02.dkfz.de/record/291915/files/1-s2.0-S095980492400889X-main.pdf
000291915 8564_ $$uhttps://inrepo02.dkfz.de/record/291915/files/1-s2.0-S095980492400889X-main.pdf?subformat=pdfa$$xpdfa
000291915 909CO $$ooai:inrepo02.dkfz.de:291915$$pVDB
000291915 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000291915 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000291915 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000291915 9141_ $$y2024
000291915 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000291915 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J CANCER : 2022$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000291915 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J CANCER : 2022$$d2023-10-21
000291915 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000291915 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000291915 980__ $$ajournal
000291915 980__ $$aVDB
000291915 980__ $$aI:(DE-He78)C070-20160331
000291915 980__ $$aI:(DE-He78)HD01-20160331
000291915 980__ $$aUNRESTRICTED